Welcome to our dedicated page for Novocure news (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on Novocure stock.
Novocure Limited (NASDAQ: NVCR) is a global oncology company centered on Tumor Treating Fields (TTFields) therapy, and its news flow reflects both commercial performance and clinical development across aggressive solid tumors. Company press releases emphasize TTFields-based products such as Optune Gio for glioblastoma and Optune Lua for metastatic non-small cell lung cancer (mNSCLC) and mesothelioma-related indications.
Investors following NVCR news will find regular updates on quarterly and annual net revenues, active patient counts on TTFields therapy, and geographic contributions from the United States and international markets. Novocure frequently reports metrics for Optune Gio and Optune Lua prescriptions, active patients by indication and region, and recognized revenue from specific products and partnerships.
News coverage also highlights clinical and regulatory milestones. Novocure issues announcements on Phase 2 and Phase 3 trials such as PANOVA-3 and PANOVA-4 in pancreatic cancer, TRIDENT in newly diagnosed glioblastoma and METIS in brain metastases from NSCLC. Releases describe key outcomes, including when pivotal trials meet primary endpoints or support regulatory submissions. The company also reports on premarket approval (PMA) applications to the U.S. Food and Drug Administration for new TTFields indications and approvals from regulators such as Japan’s Ministry of Health, Labour and Welfare for Optune Lua.
Another recurring theme in NVCR news is participation in major healthcare and oncology conferences, including the J.P. Morgan Healthcare Conference, Jefferies Global Healthcare Conference, Piper Sandler Healthcare Conference, EANO, ESMO and ASTRO. These events often feature Novocure management presentations, investor meetings and scientific data on TTFields therapy.
For readers tracking NVCR, this news page aggregates company announcements on financial results, product approvals, clinical trial data, leadership changes and scientific presentations, offering a consolidated view of developments around Novocure’s TTFields-based oncology platform.
Novocure (NASDAQ: NVCR) announced its participation in two investor conferences: the 33rd Annual Piper Sandler Healthcare Conference on November 30, 2021, and the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021. Executive Chairman William Doyle and CFO Ashley Cordova will participate in a fireside chat and one-on-one investor meetings at the Piper Sandler event, while Cordova and Chief Commercial Officer Pritesh Shah will hold meetings during the Evercore ISI conference. A live audio webcast will be available on Novocure's Investor Relations page.
Novocure announces successful enrollment completion in the phase 3 LUNAR trial for advanced stage 4 non-small cell lung cancer (NSCLC), with final data expected by year-end 2022. This pivotal study examines the efficacy of Tumor Treating Fields (TTFields) alongside immune checkpoint inhibitors or docetaxel, targeting improved overall survival rates. Annually, NSCLC affects nearly 200,000 patients in the U.S., and the trial is significant for treatment evolution. This marks Novocure's second phase 3 trial to finish enrollment this quarter, with more data anticipated in the following two years.
Novocure (NASDAQ: NVCR) announced promising results from the phase 2 pilot 2-THE-TOP trial, which evaluates Tumor Treating Fields (TTFields) combined with pembrolizumab and temozolomide for newly diagnosed glioblastoma patients. With over 9 months of follow-up, median progression-free survival was at least 11.2 months, significantly higher than the historical median of 6.7 months. The study observed a 24% response rate with partial or complete responses. The data will be presented by Dr. David Tran at the Society for Neuro-Oncology Annual Meeting on November 19, 2021.
Novocure (NASDAQ: NVCR) announced an oral presentation featuring updated data from the 2-THE-TOP study for newly diagnosed glioblastoma (GBM) patients treated with Tumor Treating Fields (TTFields), pembrolizumab, and temozolomide. The study indicated a median progression-free survival of at least 11.2 months in patients with over 9 months of follow-up. This information will be presented at the Society for Neuro-Oncology (SNO) 2021 Annual Meeting in Boston from November 18 to 21, with 31 presentations related to TTFields expected.
Novocure (NASDAQ: NVCR) announced the completion of patient enrollment in the phase 3 INNOVATE-3 trial, investigating Tumor Treating Fields (TTFields) combined with paclitaxel for treating platinum-resistant ovarian cancer.
This trial is significant, being Novocure's largest abdominal trial to date, aimed at improving outcomes for approximately 100,000 patients annually in the U.S., Europe, and Japan. The final data from this trial is expected in 2023, with a primary focus on overall survival rates.
Novocure (NASDAQ: NVCR) reported Q3 2021 net revenues of $133.6 million, a 1% increase from Q3 2020. Gross profit reached $103.4 million with a 77% gross margin. The company experienced a net loss of $13.1 million, contrasting with a net income of $9.3 million in the prior year. Significant investments included $48 million in R&D. The phase 3 INNOVATE-3 trial for recurrent ovarian cancer recently completed patient enrollment. Novocure's cash reserves were $933.8 million as of September 30, 2021, marking a $91.2 million increase from the start of the year.
Novocure (NASDAQ: NVCR) announced 15 presentations on Tumor Treating Fields (TTFields) at the ASTRO 2021 Annual Meeting, occurring from Oct. 24-27 in Chicago. Five presentations include new data on the combination of TTFields and chemoradiation for glioblastoma patients. The research underscores the growing interest in TTFields within radiation oncology. The company aims to establish TTFields as a vital treatment for solid tumors, reflecting its ongoing commitment to cancer care innovation.
Novocure (NASDAQ: NVCR) will report its third quarter 2021 financial results on October 28, 2021, before U.S. markets open. A conference call is scheduled for 8 a.m. EDT on the same day to discuss the results for the three and nine months ended September 30, 2021. Participating analysts and investors can join by dialing the provided numbers. Novocure focuses on oncology, particularly with its Tumor Treating Fields (TTFields), aimed at treating aggressive cancers like glioblastoma. The company also has numerous clinical trials ongoing across various cancers.
Novocure (NASDAQ: NVCR) and Zai Lab (NASDAQ: ZLAB) announced the enrollment of the final patient in a phase 2 pilot trial targeting gastric adenocarcinoma. This trial investigates the safety and efficacy of Tumor Treating Fields (TTFields) in combination with XELOX chemotherapy as a first-line treatment. Approximately 30 patients have been enrolled, with final data collection expected in the first half of 2022. Gastric cancer poses a significant health threat in China, highlighting the unmet medical need. Results from this trial may influence future treatment options in the region.
Novocure (NASDAQ: NVCR) announced a clinical trial collaboration with Roche to develop Tumor Treating Fields (TTFields) alongside atezolizumab for metastatic pancreatic ductal adenocarcinoma (mPDAC). This aggressive cancer has a poor prognosis, with a 5-year survival rate of only 7.2%. The Phase 2 trial will enroll around 75 patients in the EU and US, assessing safety and efficacy against established benchmarks. The collaboration aims to enhance treatment outcomes in a challenging immunotherapy setting, marking a significant step in cancer treatment innovation.